HCV Advocate Newsletter: 2017
This site includes links to files you can view online or print. To download and print information, you will need the latest version of Adobe Acrobat Reader. Download it free.
In this month’s Eblast we have a lot of information to pass on to you. At the top of the list is that a new combination of hepatitis C medications was approved by the Food and Drug Administration (FDA) to re-treat people who have not been cured with a previous course of certain direct-acting antiviral medications. You can read about it in this month’s HCV Advocate newsletter.
This month’s newsletter includes:
- HCV SnapShots by Alan Franciscus includes HCV Drugs that offers a short overview of the FDA approval of Vosevi listed above. There is also a comprehensive overview of Vosevi that can be found on our Hep C Medications Blog at http://hepatitiscmedications.hcvadvocate.org/vosevii/. It is also expected that AbbVie’s Maviret will be approved by the FDA in August.
In SnapShots I report on two studies 1) examination of acute kidney disease in a sofosbuvir-based treatment study, and 2) an analysis comparing the adherence of people who inject drugs vs. those who don’t inject drugs.
- Healthwise by Lucinda K. Porter—Life After Hepatitis C-Lucinda provides valuable information about moving on after being cured of hepatitis C and provides opinions from some of the leading experts on liver disease.
- Hepatitis C in Children by Alan Franciscus—I provide an overview of hepatitis C in children including the prevalence, transmission from mother–to-child, testing children, transmission among children, disease progression and monitoring, and treatment with direct-acting antiviral medications.
- Under the Umbrella by Matthew Zielske—Matthew discusses the HCSP Train-the-Trainer workshops he conducts and the concerns that the workshop attendees experience in their daily work trying to combat the opiate epidemic sweeping the country.
- What’s Up!
Check out five new Harm Reduction fact sheets:
Lastly, we found a glitch in our website email system. If you sent an email to us and you never received a response it is likely that it was one of the automatic email systems that was broken. The problem has been fixed and the system is working correctly. If you still need information feel free to email me at alanSCrEWfranciscus@hcvadvocate.org.
In this month’s July HCV Advocate newsletter we have the following articles for your educational and reading pleasure:
- HealthWise: World Hepatitis Day 2017 by Lucinda K. Porter, RN—Lucinda discusses the importance of World Hepatitis Day, the populations it is affecting around the world, and how various organizations are responding to the hepatitis B and C epidemic.
International Liver Conference – Part 3 – Third Time’s the Charm – This is our final coverage in the HCV Advocate newsletter.
- My coverage includes three studies: (1) a study of hepatitis C (HCV) treatment of injection drug users with Epclusa, (2) improvement of glycemic control (diabetes) in people who responded to HCV treatment with sofosbuvir-based therapies, and (3) HCV treatment in people with kidney disease.
- Matthew’s coverage includes 2 studies: (1) the treatment of HCV in post-transplant people coinfected with HIV, and (2) the outcomes of people treated with direct-acting antiviral medications while waitlisted for a liver transplant evaluated one year post-transplant.
- What’s Up!
- We have five new Harm Reduction Fact Sheets:
- Bleach: How to clean a syringe with bleach
- Injection Techniques: Techniques on safe injecting
- Naloxone: What is it and how to use it?
- Opioids: What are they and how they work?
- Vein and Artery Care: How to take care of your veins and arteries, and when to know you hit a vein or artery.
- Alan’s coverage includes: final results from a phase 3 study of glecaprevir plus pibrentasvir (one pill/once-a-day) to treat genotype 3; a phase 2 study of MK-3682/grazoprevir plus ruzasvir to treat people who previously failed direct-acting antiviral therapy; treatment with sofosbuvir/velpatasvir plus voxilaprevir (one-pill, once-a-day) in treatment experienced patients with resistance and finally a study comparing liver cancer outcomes in people achieving a cure with interferon-based therapies vs. direct-acting antiviral therapies.
- Lucinda’s coverage includes: high cure rates with legally imported generic HCV drugs; Harvoni in patients with HCV/HBV coinfection; Harvoni +/– ribavirin treatment in children with chronic hepatitis C and lastly physical activity and cardiorespiratory fitness levels in people living with hepatitis C.
- Matthew’s coverage includes: a study of a viral load point-of-care test that has the potential to improve the HCV treatment cascade and the long-term gender differences in outcomes among people with hepatitis B and hepatitis C.
- The Drug Pipeline is be updated on a monthly basis and is always included with the HCV Advocate Newsletter
- What’s Up! Have you listened to our new voiceovers? We have added voiceovers to some of our most popular Easy C fact sheets – check them out!
- Lucinda’s Highlights from ILC 2017: Marijuana and liver transplant waitlist; expanding age-based testing; health-related quality of life and children treated with sofosbuvir and ribavirin; the effect of cholesterol and low-density lipoprotein after DAA treatment, and cardiovascular and cerebrovascular effects after DAA therapy.
- Alan’s Highlight’s from ILC 2017: Prevalence of concomitant substance abuse and mental health disorders in a HCV treatment program; factors associated with spontaneous viral clearance; treatment of acute HCV in people with HIV; treatment of HCV in New Mexico prison using telemedicine.
- Matthew’s Highlight’s from ILC 2017: Group medical intervention to improve HCV uptake among PWIDs in a primary care setting; 4 weeks of DAA treatment + ribavirin +/- pegylated interferon to treat PWIDs; evaluation of homeless on HCV treatment among PWIDs.
- What’s Up!
- Monday June 5th – Vestavia, Alabama
- Wednesday June 7th –Montgomery, Alabama
We have added a voiceover feature to some of our Easy C Fact Sheets:
What are Ravs / Viral Load Test / Taking HCV Meds / Ribavirin Warning
Hepatitis B Warning / Hepatitis C Antibody Test / Drug Resistance\What is HCV Genotype?
What is ALT? / What is Subtype?
Instructions on how to listen to the voiceovers are included on an overview website page (here). I would be very interested in feedback from our readers on the current voiceovers and recommendations for voiceovers on other fact sheets. Thank You!
- HealthWise – Sleep: The Key to a Healthy Liver by Lucinda K. Porter, RN. In this month’s column Lucinda explores the connection between sleep, the liver, a person’s health and the dreaded daylight saving time.
- SnapShots—by Alan Franciscus. I discuss three studies: Zepatier to treat people with bleeding disorders, the transformation of HCV treatment from the interferon era to direct-acting antiviral era with the VA system and finally the incidence of fatty liver in people with HIV, HCV, HIV/HCV coinfection and those with neither—and the very surprising outcome from the study.
- Under the Umbrella—Five Ways Hepatitis C is Unique to Women by Matthew Zielske. Matthew lays out five important facts about women and hepatitis C that you may or may not know about women infected with hepatitis C.
- What’s Up!
- HealthWise – Why We Need to Treat Everyone Who Has Hepatitis C by Lucinda K. Porter, RN – Lucinda explores how to eliminate hepatitis C in this thought-provoking article.
- Under The Umbrella—The Pros and Cons of Learning about Hepatitis C on the Internet by Matthew Zielske—Matthew writes about the pros and cons of educating ourselves and others about hepatitis C on the internet.
- SnapShots by Alan Franciscus.In this month’s column I write about three studies—the new liver chemistry guidelines issued, potential liver injury from herbal and dietary supplements, and an analysis about the treatment using Zepatier in people with compensated cirrhosis.
- The Drug Pipeline has been pretty quiet this month with the exception of the news that AbbVie’s two drug combination of glecaprevir plus pibrentasvir to treat all genotypes (pan-genotypic) had been granted a FDA priority review-meaning that the drug approval process will be speeded up.
- What’s Up! – In this month notice we have updated the following fact sheets:
- HealthWise – Connecting the Heart and the Liver – Lucinda K. Porter, RN. Lucinda talks about the health of these important organs. The number of people who die from heart disease annually is staggering.
- Under The Umbrella—Harm Reduction and Hepatitis C – Matthew Zielske.Matthew discusses aspects of harm reduction geared towards hepatitis C transmission. He is also working on many new Harm Reduction fact sheets for the HCV Advocate Website. Three new fact sheets are listed below.
- SnapShots – Alan Franciscus. In this month’s column I cover three studies—deaths caused by hepatitis C among Mexican Americans, non-Hispanics Whites and non-Hispanic Blacks, the changes in the most common indications for liver transplants and transplant waitlists and finally, a study that looked at the best practice to screen people at risk (including Baby Boomers) for hepatitis C in an effort to increase screening. All three studies are very illuminating.
- Drug Pipeline — no changes in this month’s Drug Pipeline
- What’s Up! – New this month are three Harm Reduction Fact Sheets:
- Harm Reduction and Alcohol
- Harm Reduction and Indirect Sharing
- Harm Reduction Definitions
- Coming Mid-February: Hepatitis C Drug Pipeline and Conference Coverage – The new feature will be populated by our conference coverage from 2016, from EASL and AASLD, and future conferences as well as current and future articles about drugs in development.
- 2016 In Review: Check out what our staff picked as the top news of last year.
- Under the Umbrella – The Art of Seeing by Matthew Zielske—Matthew discusses the meaning of being an advocate – an inspiring article to bring in 2017
- HealthWise by Lucinda K. Porter RN – Lucinda writes and argues for the elimination of hepatitis C in the United States and globally.
- AASLD 2016 – Part 2 by Alan Franciscus-I write about drugs in development to treat hepatitis C, monitoring people who are at risk for liver cancer and treating hepatitis C in people who inject drugs.
- HCV Advocate Pipeline
- What’s Up!
- Paper PI – we have decided to close down the Paper PI newsletter since we cover all the news in our News and Pipeline Blog.
- HCV and Harm Reduction – we have launched a new series of fact sheets on Harm Reduction. The first piece is an Overview of Harm Reduction by Matthew Zielske.
- Easy C Fact Sheet – Hep C Prevention in a Household – A common concern for people living together. This simple fact sheet provides information on how to stay safe
- Easy C Fact Sheet – Beware of Hepatitis B – we have revised this fact sheet based on feedback. The actual cases of HBV reactivation are uncommon and occurred with pegylated interferon therapies and the new direct-acting antiviral therapies.